The actions and interactions of sex steroids and growth factors/cytokines on the skeleton

Molecular Endocrinology

Volumn 13, Issue 6, 1999, Pages 819-828

  Spelsberg, Thomas C ^a   Subramaniam, M ^a   Riggs, B Lawrence ^b   Khosla, Sundeep ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; COLLAGEN TYPE 1; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GROWTH FACTOR; HORMONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCALCIN; PROGESTERONE; PROTEIN C FOS; PROTEIN KINASE C; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1;

BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL FUNCTION; HORMONAL REGULATION; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033305457     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.6.0299     Document Type: Short Survey

References (62)

1. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
2. Estrogens and Progestins
3. Estrogen regulation of gene expression in osteoblasts and osteoclasts
4. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update
5. Interleukins in the control of osteoclast differentiation
6. Sex steroid effects on bone metabolism
7. Evidence of estrogen receptors in normal human osteoblast-like cells
8. Avian osteoclasts as estrogen target cells
9. Estrogen receptor mRNA is expressed in vivo in rat calvarial periosteum
10. Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction
11. Expression of estrogen receptor beta in rat bone
12. Estrogen receptor-α is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression
13. Estrogen regulation of human osteoblastic cell proliferation and differentiation
14. Mice, estrogen and postmenopausal osteoporosis
15. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production
16. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
17. Estrogen stimulates gene expression and protein production of osteoprotegerin by human osteoblastic cells
18. Estrogen regulation of a TGF-β inducible early gene that inhibits DNA synthesis in human osteoblasts
19. Bone morphogenetic protein-6 production in human osteoblastic cell lines: Selective regulation by estrogen
20. Repression of the IL-6 promoter by ER is mediated by NF-κB and c/EBPβ
21. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow: Evidence for autonomy from factors released during bone resorption
22. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
23. Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes
24. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor α and β
25. Mouse estrogen receptor β forms estrogen response element binding heterodimers with estrogen receptor-α
26. Differential ligand activation of estrogen receptors ER-α and ER-β at AP-1 sites
27. Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells
28. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells
29. A human homolog of the 150 kD avian osteoclast membrane antigen related to superoxide dismutase and essential for bone resorption is induced by developmental agents and opposed by estrogen in FLG 29.1 cells
30. Estrogen decreases the steady state levels of the IL-1 signaling receptor (Type I) while increasing those of the IL-1 decoy receptor (Type II) mRNAs in human osteoclast-like cells
31. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone resorbing osteoclasts
32. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β
33. Osteoclasts from human giant cell tumors of bone lack estrogen receptors
34. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/progesterone therapy
35. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
36. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency
37. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
38. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
39. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae
40. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
41. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
42. Osteoprotegerin (OPG), a novel TNF-receptor family member profoundly inhibits endosteal bone resorption due to growth, humoral hypercalcemia of malignancy, and interleukin-1
43. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
44. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
45. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
46. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
47. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period
48. Transforming growth factorβ gene family members, their receptors, and bone cell function
49. Identification of a novel TGF-β regulated gene encoding a putative zinc finger protein in human osteoblasts
50. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
51. Molecular basis of agonism and antagonism in the oestrogen receptor
52. Estrogen receptorβgetting in on the action?
53. The novel estrogen receptor-β subtype: Potential role in the cell- and promoter-specific actions of estrogens and antiestrogens
54. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone
55. Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats
56. Estrogen metabolites in urine of early postmenopausal women correlate with bone density and rate of bone loss
57. Effects of gonadal and adrenal androgens in a novel androgen responsive human osteoblastic cell line
58. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor
59. Androgen, the antiandrogen hydroxyflutamide inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line
60. Regulation of c-fos expression and TGF-β production by gonadal and adrenal androgens in normal human osteoblastic cells